This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Treatment With PROVENGE® (sipuleucel-T) Induces Antigen Spread Associated With Overall Survival Benefits In Advanced Prostate Cancer

May 20, 2014-Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of data from the ProACT and IMPACT studies suggesting that PROVENGE ® (sipuleucel-T) elicits an immune response associated with an overall survival benefit. Also being presented are data from the PROCEED registry suggesting similar treatment patterns for urologists and oncologists in PROVENGE-treated patients with metastatic castration-resistant prostate cancer (mCRPC). The ProACT and IMPACT data will be reported in a podium presentation and the PROCEED data will be included in a general poster session during the 2014 American Urological Association (AUA) Annual Meeting from May 16-21, 2014 in Orlando, Florida.

“These data further elucidate the mechanism of PROVENGE in the treatment of mCRPC and the important role immunotherapy plays in the prescribing practices of urologists and oncologists, which may improve outcomes for patients,” said Andrew S. Sandler, M.D., executive vice president and chief medical officer at Dendreon. “The elevated immune response against prostate-specific antigen (PSA) in the ProACT and IMPACT studies is correlated with overall survival, and may point to a useful biomarker of treatment benefit.”

Clinical presentations featuring PROVENGE studies at the annual scientific urology meeting include:
  • Abstract PD27-04: Simon Hall, M.D., associate professor of urology at Mt. Sinai Hospital, will present “ Sipuleucel-T-Induced Antigen Spread: Immune Response to Prostate-Specific Antigen Correlates with Improved Overall Survival:” Data from the Phase III IMPACT and Phase II ProACT studies show evidence that antigen spread may occur after PROVENGE treatment, indicating the immune response evolves over time to target multiple prostate antigens. These data may help identify biomarkers of clinical outcome after treatment with PROVENGE. May 20,8:00 AM – 10:00 AM ET, Prostate Cancer: Advanced I (Podium Presentation, Room W304E)
  • Abstract MP70-20: Matthew R. Cooperberg, M.D., M.P.H, associate professor of urology at University of California, San Francisco, will present a poster titled “ Treatment Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Prior to Receiving Sipuleucel-T: Data from PROCEED:” A subgroup analysis from the ongoing Phase IV registry of mCRPC patients suggest treatment patterns between urologists and oncologists are similar, helping to better understand prescribing trends prior to and following use of PROVENGE. May 20,10:30 AM – 12:30 PM ET, Prostate Cancer: Advanced II (Moderated Poster Session, Room W307)

“The evolution of immunotherapy treatment continues to be a focus for the future of urology research, as evidenced in the PROVENGE data presented at AUA,” said Simon Hall. M.D., associate professor of urology at Mt. Sinai Hospital. “The biomarker potential of the anti-PSA immune response suggested in the IMPACT and ProACT data is exciting as it continues to reinforce the positive impact immunotherapies and PROVENGE may have on patients with mCRPC.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs